[go: up one dir, main page]

WO2024122949A1 - Marqueur pour le diagnostic ou le suivi de l'ostéosarcopénie, et son utilisation - Google Patents

Marqueur pour le diagnostic ou le suivi de l'ostéosarcopénie, et son utilisation Download PDF

Info

Publication number
WO2024122949A1
WO2024122949A1 PCT/KR2023/019088 KR2023019088W WO2024122949A1 WO 2024122949 A1 WO2024122949 A1 WO 2024122949A1 KR 2023019088 W KR2023019088 W KR 2023019088W WO 2024122949 A1 WO2024122949 A1 WO 2024122949A1
Authority
WO
WIPO (PCT)
Prior art keywords
osteosarcopenia
rna
col3a1
col1a2
col1a1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2023/019088
Other languages
English (en)
Korean (ko)
Inventor
강정현
홍석우
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajou University Industry Academic Cooperation Foundation
Samsung Medical Center
Original Assignee
Ajou University Industry Academic Cooperation Foundation
Samsung Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajou University Industry Academic Cooperation Foundation, Samsung Medical Center filed Critical Ajou University Industry Academic Cooperation Foundation
Publication of WO2024122949A1 publication Critical patent/WO2024122949A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders

Definitions

  • the present invention relates to a marker for diagnosing or monitoring osteosarcopenia and its use.
  • Skeletal muscle and bone are dynamic organs that continuously interact with each other to meet the demands of the surrounding environment and maintain metabolic homeostasis. These are the two main components that make up the musculoskeletal system through mechanical leveraging and chemical interactions. Skeletal muscles attach to associated bones close to the axis of motion and create horizontal arms to generate the torque required for movement. Biochemical interactions between bone and muscle are mediated through factors such as myokines, osteokines, adiponectin, senescence-associated secretory phenotype, and micro RNA. do. The combination of mechanical loading and biochemical signals appears to be synergistic and provides stronger effects than either stimulus alone, but the exact mechanism between them is not clearly understood.
  • RNA-sequencing technology based on Next Generation Sequencing technology has been used as a powerful tool to identify potential molecular background or therapeutic targets at a glance in various disease-related studies. RNA sequencing technology has never been applied for the purpose of elucidating the pathogenesis and muscle-bone interactions of osteosarcopenia.
  • Patent Document 1 KR 10-2020-0049147 (2020-04-23)
  • the present inventors sought to uncover the molecular mechanism between muscle and bone and identify potential therapeutic targets for osteosarcopenia by analyzing the transcriptional profile of total RNA in muscle tissue of women with distal radius fractures and sarcopenia.
  • the purpose of the present invention is to provide a marker for diagnosing or monitoring osteosarcopenia and its use.
  • the present invention provides a composition for diagnosing or monitoring osteosarcopenia, comprising an agent for measuring the expression level of one or more selected from the group consisting of MMP2, MMP14, COL1A1, COL1A2, and COL3A1.
  • the agent is an agent that measures the expression level of protein or RNA.
  • the present invention provides a kit for diagnosing or monitoring osteosarcopenia comprising the composition.
  • the present invention provides a method of providing information for diagnosing osteosarcopenia, comprising measuring the expression level of one or more selected from the group consisting of MMP2, MMP14, COL1A1, COL1A2, and COL3A1 in a sample isolated from an individual. .
  • the information provision method includes the step of isolating osteosarcopenia when the expression level of any one or more selected from the group consisting of MMP2, MMP14, COL1A1, COL1A2, and COL3A1 is increased compared to the normal control group. It is additionally included.
  • the present invention provides a method for monitoring osteosarcopenia, comprising measuring the expression level of one or more selected from the group consisting of MMP2, MMP14, COL1A1, COL1A2, and COL3A1.
  • the present invention provides a use for diagnosing or monitoring osteosarcopenia of a composition containing an agent that measures the expression level of one or more selected from the group consisting of MMP2, MMP14, COL1A1, COL1A2, and COL3A1.
  • the present invention provides a use for preparing a composition for diagnosing or monitoring osteosarcopenia, comprising an agent for measuring the expression level of any one or more selected from the group consisting of MMP2, MMP14, COL1A1, COL1A2, and COL3A1. .
  • the present invention provides a method for diagnosing osteosarcopenia, which includes measuring the expression level of one or more selected from the group consisting of MMP2, MMP14, COL1A1, COL1A2, and COL3A1 in a sample isolated from an individual.
  • Ostosarcopenia (sarco-osteoporosis)” of the present invention may refer to a disease in which sarcopenia and osteoporosis occur simultaneously.
  • Diagnosis in the present invention means, in a broad sense, judging the actual condition of a patient's disease in all aspects. The contents of the judgment include the name of the disease, etiology, type, severity, detailed conditions of the disease, and the presence or absence of complications. In the present invention, the diagnosis is preferably to determine osteosarcopenia and the risk of developing it.
  • “Monitoring” of the present invention refers to observing the occurrence of osteosarcopenia in a normal person or a patient suspected of having a disease, observing the progress of a patient with a disease before and/or after treatment, or using therametrics (e.g. , monitoring the condition of the object to provide information on treatment efficacy).
  • the present invention can provide a composition for diagnosing or monitoring osteosarcopenia, which includes an agent for measuring the expression level of one or more selected from the group consisting of MMP2, MMP14, COL1A1, COL1A2, and COL3A1.
  • the agent may be an agent that measures the expression level of protein or RNA.
  • the RNA may be messenger RNA (mRNA), microRNA (miRNA), small nucleolar RNA (snoRNA), ribosomal RNA (rRNA), transfer RNA (tRNA), small interfering RNA (siRNA), heterogeneous nuclear RNA (hnRNA), or small hairpin RNA. It may be RNA (shRNA).
  • the present invention can provide a kit for diagnosing or monitoring osteosarcopenia containing the above composition.
  • kits of the present invention may be composed of one or more different component compositions, solutions, or devices suitable for commonly used expression level analysis methods.
  • a kit for measuring protein expression levels may include a substrate, an appropriate buffer solution, a secondary antibody labeled with a chromogenic enzyme or a fluorescent substance, a chromogenic substrate, etc. for immunological detection of an antibody.
  • the kit of the present invention may include a sample extraction means for obtaining a sample from an evaluation subject.
  • the sample extraction means may include a needle or syringe.
  • the kit may include a sample collection container to contain the extracted sample, which may be liquid, gaseous, or semi-solid. Kits may additionally include instructions for use.
  • the sample may be any body sample in which a marker may be present or secreted.
  • the sample can be tissue, cells, whole blood, serum, plasma, saliva, urine, feces, sweat, or cerebrospinal fluid. Measurement of markers in body samples can be performed on whole samples or processed samples.
  • the present invention provides a method for providing information for diagnosing osteosarcopenia, which includes measuring the expression level of one or more selected from the group consisting of MMP2, MMP14, COL1A1, COL1A2, and COL3A1 in a sample isolated from an individual. You can.
  • the sample may be tissue, cells, whole blood, serum, plasma, saliva, urine, stool, sweat, or cerebrospinal fluid.
  • the sample may be tissue or cells, more preferably muscle tissue or cells.
  • the information provision method includes the step of isolating osteosarcopenia when the expression level of any one or more selected from the group consisting of MMP2, MMP14, COL1A1, COL1A2, and COL3A1 is increased compared to the normal control group. It may be included additionally.
  • the normal control group may refer to an individual that does not exhibit sarcopenia or osteoporosis or a sample isolated therefrom.
  • the agent may be an agent that measures the expression level of protein or RNA.
  • the RNA may be messenger RNA (mRNA), microRNA (miRNA), small nucleolar RNA (snoRNA), ribosomal RNA (rRNA), transfer RNA (tRNA), small interfering RNA (siRNA), heterogeneous nuclear RNA (hnRNA), or small hairpin RNA. It may be RNA (shRNA).
  • the present invention can provide a method for monitoring osteosarcopenia, which includes measuring the expression level of one or more selected from the group consisting of MMP2, MMP14, COL1A1, COL1A2, and COL3A1.
  • the agent may be an agent that measures the expression level of protein or RNA.
  • the RNA may be messenger RNA (mRNA), microRNA (miRNA), small nucleolar RNA (snoRNA), ribosomal RNA (rRNA), transfer RNA (tRNA), small interfering RNA (siRNA), heterogeneous nuclear RNA (hnRNA), or small hairpin RNA. It may be RNA (shRNA).
  • the present invention provides a use for diagnosing or monitoring osteosarcopenia of a composition containing an agent for measuring the expression level of any one or more selected from the group consisting of MMP2, MMP14, COL1A1, COL1A2, and COL3A1.
  • the agent may be an agent that measures the expression level of protein or RNA.
  • the RNA may be messenger RNA (mRNA), microRNA (miRNA), small nucleolar RNA (snoRNA), ribosomal RNA (rRNA), transfer RNA (tRNA), small interfering RNA (siRNA), heterogeneous nuclear RNA (hnRNA), or small hairpin RNA. It may be RNA (shRNA).
  • the present invention provides a use for preparing a composition for diagnosing or monitoring osteosarcopenia, comprising an agent for measuring the expression level of any one or more selected from the group consisting of MMP2, MMP14, COL1A1, COL1A2, and COL3A1. .
  • the agent may be an agent that measures the expression level of protein or RNA.
  • the RNA may be messenger RNA (mRNA), microRNA (miRNA), small nucleolar RNA (snoRNA), ribosomal RNA (rRNA), transfer RNA (tRNA), small interfering RNA (siRNA), heterogeneous nuclear RNA (hnRNA), or small hairpin RNA. It may be RNA (shRNA).
  • the present invention provides a method for diagnosing osteosarcopenia, which includes measuring the expression level of one or more selected from the group consisting of MMP2, MMP14, COL1A1, COL1A2, and COL3A1 in a sample isolated from an individual.
  • the sample may be tissue, cells, whole blood, serum, plasma, saliva, urine, feces, sweat, or cerebrospinal fluid.
  • the sample may be tissue or cells, more preferably muscle tissue or cells.
  • the diagnostic method additionally includes the step of isolating osteosarcopenia when the expression level of any one or more selected from the group consisting of MMP2, MMP14, COL1A1, COL1A2, and COL3A1 is increased compared to the normal control group. It may include
  • the normal control group may refer to an individual that does not exhibit sarcopenia or osteoporosis or a sample isolated therefrom.
  • the expression level may be that of protein or RNA.
  • the RNA may be messenger RNA (mRNA), microRNA (miRNA), small nucleolar RNA (snoRNA), ribosomal RNA (rRNA), transfer RNA (tRNA), small interfering RNA (siRNA), heterogeneous nuclear RNA (hnRNA), or small hairpin RNA. It may be RNA (shRNA).
  • the present invention can provide markers that can be used to diagnose or monitor osteosarcopenia, particularly MMP2, MMP14, COL1A1, COL1A2, or COL3A1, derived using RNA sequencing (RNA-seq) technology.
  • markers that can be used to diagnose or monitor osteosarcopenia, particularly MMP2, MMP14, COL1A1, COL1A2, or COL3A1, derived using RNA sequencing (RNA-seq) technology.
  • Figure 1 shows a three-dimensional reconstructed distal radius model for calculating the distal radius cortical bone thickness and the average density of cortical and cancellous bone.
  • Figure 2a is a volcano plot showing the DEG differential expression results in the normal control group (NORM) and osteosarcopenia group (OSTEOSARCO), respectively.
  • Figure 2b is a scatter plot showing the DEG differential expression results in the normal control group (NORM) and osteosarcopenia group (OSTEOSARCO), respectively.
  • Figure 2c is the principle component analysis results showing the DEG differential expression results in the normal control group (NORM) and the osteosarcopenia group (OSTEOSARCO), respectively.
  • Figure 2d is an unsupervised clustering result showing the DEG differential expression results in the normal control group (NORM) and osteosarcopenia group (OSTEOSARCO), respectively.
  • Figure 3a shows the biological pathway as a result of Gene Ontology (GO) analysis analyzed through DAVID.
  • Figure 3b shows the molecular pathway as a result of Gene Ontology (GO) analysis analyzed through DAVID.
  • Figure 3c shows the cellular component as a result of Gene Ontology (GO) analysis analyzed through DAVID.
  • Figure 4a shows a network related to collagen synthesis according to IPA analysis.
  • Figure 4b shows the network related to MMP2 and MMP14 according to the IPA analysis results.
  • Figure 5 shows the results of real-time PCR analysis of the gene expression patterns of five hub genes, including COL1A1, COL1A2, COL3A1, MMP2, and MMP14 transcripts, which showed significant results in both GO analysis and IPA analysis.
  • One orthopedic surgeon performed all surgeries, including open reduction and internal fixation, using a volar plate fixation device.
  • disorders that may affect bone and muscle metabolism such as malignancy, thyroid disorders, uncontrolled diabetes mellitus, neurodegenerative diseases, rheumatoid arthritis, liver disease, and kidney failure, or hormone modulators, anabolic agents, bisphosphonates, denosumab , Patients unable to communicate were excluded.
  • a trained nurse assessed each participant's height, weight, and calf and forearm circumference.
  • Handgrip strength was determined by a hand dynamometer (Jamar®5030J1, Sammons Preston Rolyan, Bolingbrook, IL, USA) in the contralateral uninjured hand by a single orthopedic surgeon (SWH). Each participant performed three grip strength measurements and then calculated the average value. If the dominant hand was injured, grip strength was assessed using the 10% rule. The diagnosis of sarcopenia was based on grip strength.
  • aBMD Areal bone mineral density (aBMD, grams per square centimeter) of the total hip, femoral neck, and lumbar spine (L1-L4) was measured by dual-energy X-ray absorptiometry with a Hologic device (Horizon-W; Hologic Inc., Bedford, MA, USA). It was measured using DEXA).
  • the T scores of aBMDs of the entire hip, femoral neck, and lumbar spine were evaluated based on aBMD values according to the standard technique of the Korean Osteoporosis Society software. Diagnosis of osteoporosis was performed according to the T-score obtained from aBMD of the femoral neck.
  • Wrist CT images were taken immediately after closed reduction of the fracture in the emergency department and before open reduction surgery using a 256-slice multidetector CT scanner (Brilliance iCT 256, Philips Medical Systems, Amsterdam, the Netherlands).
  • the scanning protocol was described as follows: 120 kVp tube potential; 149 mAs tube current-time product; 128 mm ⁇ 0.625 mm section collimation; 0.5ms rotation time; 0.4 pitch; 180mm display viewing angle; Pixel size 0.3mm ⁇ 0.3mm; and 1 mm section thickness.
  • Corrected coronal, sagittal, and axial images of the wrist were saved as Digital Imaging and Communications in Medicine (DICOM) files.
  • DICOM Digital Imaging and Communications in Medicine
  • DICOM format files were reconstructed using 3D reconstruction modeling software (Mimics 22.0, Materialize, Antwerp, Belgium).
  • a 2 cm long cylindrical bone model was constructed 3 cm proximal to the lunate fossa of the radius.
  • a global threshold of 200 hounsfield units (HU) was adopted for CT scan images to construct a representation of the 3D wrist bone model, and 850 HU was used to obtain cortical bone structures.
  • the average cortical and trabecular bone HU, total HU, and cortical thickness of the wrist bone model were automatically calculated using Mimics 22.0® software and 3 matics 14.0® software (Materialise, Antwerp, Belgium) (Figure 1).
  • a single orthopedic surgeon collected all muscle samples during open reduction and internal fixation procedures for distal radius fractures.
  • SWH single orthopedic surgeon
  • a 4-cm longitudinal incision was made along the radial border of the flexor carpi radialis (FCR) tendon.
  • the FCR tendon was retracted ulnarly, and the dorsal aspect of the FCR sheath was incised to expose the flexor hallucis longus tendon.
  • the flexor hallucis longus tendon was also retracted ulnarly, exposing the pronator quadratus muscle.
  • the pronator minor muscle (1 ⁇ 1 ⁇ 2 mm 3 ) was harvested from all participants during muscle elevation at the distal radius.
  • the myoma was placed in a cryotube, frozen in liquid nitrogen, and stored at -80°C until analysis.
  • GO Gene Ontology analysis was performed to analyze biological processes, molecular functions, and cellular components.
  • Biological processes of upregulated genes identified by GO analysis included collagen biosynthetic process, osteoblast differentiation, ossification, bone development, wound healing, and skeletal system development ( Figure 3a).
  • molecular functions and cellular components include mechanisms related to the maintenance of extracellular matrix structure and collagen synthesis ( Figure 3b, Figure 3c). Therefore, the role of enthesal muscles in maintaining bone density and developing osteosarcopenia may be related to collagen biosynthetic activity, ossification, and maintenance of the extracellular matrix structure of muscle fibers.
  • IPA identified seven annotated canonical pathways that were significantly upregulated (
  • qRT-PCR quantitative real-time polymerase chain reaction
  • the present invention can provide markers that can be used for diagnosing or monitoring osteosarcopenia, especially MMP2, MMP14, COL1A1, COL1A2 or COL3A1, derived using RNA sequencing (RNA-seq) technology, and thus has industrial applicability. there is.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un marqueur permettant de diagnostiquer ou de suivre l'ostéosarcopénie, ainsi que son utilisation. La présente invention peut procurer le marqueur qui peut être utilisé dans le diagnostic ou le suivi de l'ostéosarcopénie par une technique de séquençage de l'ARN (ARN-seq), le marqueur étant spécifiquement MMP2, MMP14, COL1A1, COL1A2 ou COL3A1.
PCT/KR2023/019088 2022-12-09 2023-11-24 Marqueur pour le diagnostic ou le suivi de l'ostéosarcopénie, et son utilisation Ceased WO2024122949A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020220171447A KR20240086178A (ko) 2022-12-09 2022-12-09 골근감소증 진단 또는 모니터링을 위한 마커 및 이의 용도
KR10-2022-0171447 2022-12-09

Publications (1)

Publication Number Publication Date
WO2024122949A1 true WO2024122949A1 (fr) 2024-06-13

Family

ID=91379525

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/019088 Ceased WO2024122949A1 (fr) 2022-12-09 2023-11-24 Marqueur pour le diagnostic ou le suivi de l'ostéosarcopénie, et son utilisation

Country Status (2)

Country Link
KR (1) KR20240086178A (fr)
WO (1) WO2024122949A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022092294A1 (fr) * 2020-10-30 2022-05-05 学校法人慶應義塾 Nouveau traitement et nouvelle prévention de maladies liées à la sarcopénie

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200049147A (ko) 2018-10-31 2020-05-08 (주)양수금속 브라켓 간격 조정이 가능한 배관용 흔들림 방지버팀대

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022092294A1 (fr) * 2020-10-30 2022-05-05 学校法人慶應義塾 Nouveau traitement et nouvelle prévention de maladies liées à la sarcopénie

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AL SAEDI AHMED, HASSAN EBRAHIM BANI, DUQUE GUSTAVO: "The diagnostic role of fat in osteosarcopenia", JOURNAL OF LABORATORY AND PRECISION MEDICINE, vol. 4, 25 February 2019 (2019-02-25), pages 7 - 7, XP093178158, ISSN: 2519-9005, DOI: 10.21037/jlpm.2019.02.01 *
HIRSCHFELD H. P.; KINSELLA R.; DUQUE G.: "Osteosarcopenia: where bone, muscle, and fat collide", OSTEOPOROSIS INTERNATIONAL, SPRINGER LONDON, LONDON, vol. 28, no. 10, 22 July 2017 (2017-07-22), London, pages 2781 - 2790, XP036331470, ISSN: 0937-941X, DOI: 10.1007/s00198-017-4151-8 *
KANG YANG-JAE, YOO JUN-IL, BAEK KYUNG-WAN: "Differential gene expression profile by RNA sequencing study of elderly osteoporotic hip fracture patients with sarcopenia", JOURNAL OF ORTHOPAEDIC TRANSLATION, vol. 29, 1 July 2021 (2021-07-01), pages 10 - 18, XP093075894, ISSN: 2214-031X, DOI: 10.1016/j.jot.2021.04.009 *
SHINYA WATANABE, KOJI SATO, NATSUKI HASEGAWA, TOSHIYUKI KURIHARA, KENJI MATSUTANI, KIYOSHI SANADA, TAKAFUMI HAMAOKA, SATOSHI FUJIT: "Serum C1q as a novel biomarker of sarcopenia in older adults", THE FASEB JOURNAL, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, US, vol. 29, no. 3, 1 March 2015 (2015-03-01), US, pages 1003 - 1010, XP055460611, ISSN: 0892-6638, DOI: 10.1096/fj.14-262154 *
SUZAN VEYSEL, BEKTAN KANAT BAHAR, YAVUZER HAKAN, BOLAYIRLI İBRAHIM MURAT, DÖVENTAŞ ALPER, ERDINÇLER DENIZ SUNA: "Association of Primary Sarcopenia with Serum MMP2, TIMP2 Levels, and MMP2/TIMP2 Ratio", EUROPEAN JOURNAL OF GERIATRICS AND GERONTOLOGY, vol. 4, no. 2, 1 August 2022 (2022-08-01), pages 46 - 51, XP093178162, ISSN: 2687-2625, DOI: 10.4274/ejgg.galenos.2021.2021-10-3 *

Also Published As

Publication number Publication date
KR20240086178A (ko) 2024-06-18

Similar Documents

Publication Publication Date Title
Fang et al. Barcoded sequencing reveals diverse intrauterine microbiomes in patients suffering with endometrial polyps
Buchgreitz et al. Frequency of headache is related to sensitization: a population study
Xu et al. Microbial biomarkers of common tongue coatings in patients with gastric cancer
Liu et al. Prenatal diagnosis of fetal skeletal dysplasia using targeted next-generation sequencing: an analysis of 30 cases
Han et al. Tongue images and tongue coating microbiome in patients with colorectal cancer
Chen et al. Microbiome of the lower genital tract in Chinese women with endometriosis by 16s-rRNA sequencing technique: a pilot study
Longo et al. Colistin resistance emerges in pandrug-resistant Klebsiella pneumoniae epidemic clones in Rio de Janeiro, Brazil
WO2016186360A1 (fr) Procédé de diagnostic de l'apparition précoce de la maladie d'alzheimer ou d'un trouble cognitif léger
WO2022025387A1 (fr) Biomarqueur pour diagnostiquer une stéatohépatite non alcoolique à l'aide d'une combinaison de miarn
Gupta et al. The molecular basis of loss of smell in 2019-nCoV infected individuals
US11124832B2 (en) Serum miRNA marker for OPLL diagnosis and application thereof
WO2019146966A1 (fr) Méthode de diagnostic d'un cholangiocarcinome par l'intermédiaire d'une analyse métagénomique bactérienne
WO2024122949A1 (fr) Marqueur pour le diagnostic ou le suivi de l'ostéosarcopénie, et son utilisation
WO2019147080A1 (fr) Méthode de diagnostic de la dépression par l'intermédiaire d'une analyse métagénomique bactérienne
WO2024123091A1 (fr) Diagnostic du cancer colorectal fondé sur le microbiote fécal
Raz et al. Molecular signatures of age-associated chronic degeneration of shoulder muscles
Yang et al. Study on tongue coating microbes of bitter taste, sticky and greasy taste in chronic atrophic gastritis
KR20210153023A (ko) 소음성 난청 또는 급성 소음성 난청을 진단하기 위한 바이오마커 및 이의 용도
Mansson Diagnosis of acute corrosive lesions of the oesophagus
Glasson et al. Diagnosis of Rett syndrome: can a radiograph help?
WO2021112612A1 (fr) Composition de biomarqueur pour prédire la réponse d'un patient atteint d'un cancer du col de l'utérus à une chimio-radiothérapie
WO2020080739A1 (fr) Composition pour le diagnostic de l'hyperprolactinémie, et procédé pour fournir des informations permettant de prédire une réponse à un traitement médicamenteux
Santamaria et al. Microbiological profile of molars with advanced furcation defects before and after surgical and non-surgical periodontal treatment: A pilot randomized controlled trial
Xie et al. Alterations of biliary and gut microbiota in relation to gallstone formation
Lei et al. Chronic Critical Illness-induced Muscle Atrophy: Insights from a Trauma Mouse Model and Potential Mechanism Mediated via Serum Amyloid A

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23900968

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23900968

Country of ref document: EP

Kind code of ref document: A1